依达拉奉治疗急性脑梗死的临床研究

目的观察依达拉奉治疗急性脑梗死的临床疗效及其安全性。方法将116例48h内发病的急性脑梗死患者随机分为依达拉奉治疗组（治疗组）和常规治疗组（对照组）,对照组应用甘油果糖、阿司匹林、丹参注射液等药物对症治疗,治疗组在常规治疗的基础上静脉输注依达拉奉30mg,2次/d,共14d。在治疗第7、14、21天进行欧洲卒中（ESS）判断治疗效果。结果治疗后第21天治疗组及对照组有效率分别为57%和24.6%,治疗组的疗效明显优于对照组。治疗组与对照组不良反应发生率分别为6.2%和5.4%。结论依达拉奉作为脑保护剂治疗急性脑梗死,疗效确切,无明显严重不良反应,可明显改善患者的预后。

Clinical Analyse on Edaravone in the Treatment of Acute Cerebral Infarction

Objective To evaluate the clinical efficacy and safety of edaravone in acute cerebral infarctions(ACI).Methods One handred and sixteen cases of ACI were randomized into edaravone group(treatment group) and basic group(control group),The control group received Glycerine furctose、Aspirin、Miltiorrhiza injection while the treatment group received edaravone 30 mg dissolved in sodium chloride injection 250 ml,twice a day,for 14 d.At 7d、14d、21d after treatment,European Stroke Scale(ESS) were used to evaluate the recovery of neurological.Results After 21d of treatment,the effective rate in treatment group and control group were 57% and 24.6% respectively,While the adverse reactions occurred were 6.2% and 5.4% in the two groups.Conclusion Edaravon used in ACI as cerebral protection,the clinical effects is definity and without conspicuous adverse reactions,and improve prognosis conspicuously.